BERKELEY, CA--(Marketwired - March 02, 2016) - Dynavax Technologies Corporation (
The live or replayed versions of the webcast will be available by visiting the "Investors" section of the Dynavax website.
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com.
Contact Information:
Contact:
Michael Ostrach
Chief Financial Officer
510-665-7257